BMED achieved record-breaking financial performance in 2024, with net income reaching €1.12 billion, a 36% increase from 2023, driven by strong performance fees of €370 million and a double-digit surge in net commission income.
Total net inflows reached €10.4 billion, a 46% increase year-on-year, with €7.6 billion directed into managed assets, setting a new all-time high for the company.
The company provided 2025 guidance, expecting net inflows into managed assets of €7.5 billion, a 5% decrease in net interest income due to yield curve expectations, and a cost-income ratio below 40%.
A base dividend increase to €0.75 per share was proposed, alongside a special dividend of €0.25 per share, reflecting the extraordinary performance in 2024.
BMED emphasized its focus on organic growth, supported by an expanding customer base and sales network, while maintaining a strong capital position with a CET1 ratio of 17.8%, despite upcoming Basel IV regulatory impacts.